Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Rituximab and Combination Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

This study has been completed.
Sponsor:
Collaborators:
National Cancer Institute (NCI)
Genentech, Inc.
Information provided by (Responsible Party):
Julie M Vose, MD, University of Nebraska
ClinicalTrials.gov Identifier:
NCT00007852
First received: January 6, 2001
Last updated: March 23, 2012
Last verified: March 2012
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: January 2011
  Primary Completion Date: January 2002 (Final data collection date for primary outcome measure)